Soluble low-density lipoprotein receptor-related protein 1 in juvenile idiopathic arthritis

the BBOP Study Group

doi:10.3899/jrheum.200391

Soluble low-density lipoprotein receptor-related protein 1 in juvenile idiopathic arthritis

the BBOP Study Group

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

1 Cita (Scopus)

Resumen

Objectives. This study aimed to expand knowledge about soluble low-density lipoprotein receptor-related protein 1 (sLRP1) in juvenile idiopathic arthritis ( JIA) by determining associations of sLRP1 levels in nonsystemic JIA patients with clinical and inflammatory biomarker indicators of disease activity. Methods. Plasma sLRP1 and 44 inflammation-related biomarkers were measured at enrollment and 6 months later in a cohort of 96 newly diagnosed Canadian patients with nonsystemic JIA. Relationships between sLRP1 levels and indicators of disease activity and biomarker levels were analyzed at both visits. Results. At enrollment, sLRP1 levels correlated negatively with age and active joint counts. Children showed significantly higher levels of sLRP1 than adolescents (mean ranks: 55.4 and 41.9, respectively; P = 0.02). Participants with 4 or fewer active joints, compared to those with 5 or more active joints, had significantly higher sLRP1 levels (mean ranks: 56.2 and 40.7, respectively; P = 0.006). At enrollment, considering the entire cohort, sLRP1 correlated negatively with the number of active joints (r = -0.235, P = 0.017). In the entire cohort, sLRP1 levels at enrollment and 6 months later correlated with 13 and 6 pro- and antiinflammatory biomarkers, respectively. In JIA categories, sLRP1 correlations with inflammatory markers were significant in rheumatoid factor-negative polyarticular JIA, oligoarticular JIA, enthesitis-related arthritis, and psoriatic arthritis at enrollment. Higher sLRP1 levels at enrollment increased the likelihood of absence of active joints 6 months later. Conclusion. Plasma sLRP1 levels correlate with clinical and biomarker indicators of short-term improvement in JIA disease activity, supporting sLRP1 as an upstream biomarker of potential utility for assessing JIA disease activity and outcome prediction.

Idioma original	English
Páginas (desde-hasta)	760-766
Número de páginas	7
Publicación	Journal of Rheumatology
Volumen	48
N.º	5
DOI	https://doi.org/10.3899/jrheum.200391
Estado	Published - may. 1 2021
Publicado de forma externa	Sí

Nota bibliográfica

Funding Information:
The BBOP Study was supported by The Canadian Institutes of Health Research (FRN #82517); The Arthritis Society (Canada), Canadian Arthritis Network (SRI-IJD-01); University of Saskatchewan; The Clinical Research Centre of the Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; McGill University; Memorial University; Manitoba Institute of Child Health; Children’s Health Research Trust Fund; Jim Pattison Children’s Hospital Foundation of Saskatchewan; The Pediatric Rheumatic Disease Research and Innovation Laboratory, University of Saskatchewan; The Haslam Research Fund, University of Saskatchewan; and The Kleiman Fund, University of Saskatchewan. 1E. Rezaei, MD, PhD, A.M. Rosenberg, MD, Departments of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan; 2M.M. Newkirk, PhD, Department of Medicine, McGill University Health Center, Montreal, Quebec; 3Z. Li, MSc, RC-CHUM, University of Montreal, Montreal, Quebec; 4J.R. Gordon, PhD, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan; 5K.G. Oen, MD, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba; 6S.M. Benseler, MD, PhD, Department of Pediatrics, Alberta Children’s Hospital, University of Calgary, Calgary, Alberta; 7G. Boire, MD, Département de Médecine, Université de Sherbrooke, Sherbrooke, Quebec; 8D.A. Cabral, MD, K. Houghton, MD, K.A. Morishita, MD, R.E. Petty, MD, PhD, L.B. Tucker, MD, S.E. Turvey, MD, Department of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia; 9S. Campillo, MD, G. Chédeville, MD, R. Scuccimarri, MD, Department of Pediatrics, McGill University Health Center, Montreal, Quebec; 10A.L. Chetaille, MD, Département de Médecine le Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec; 11P. Dancey, MD, Department of Pediatrics, Janeway Children’s Health and Rehabilitation Centre, St. John’s, Newfoundland; 12C. Duffy, MD, R. Jurencak, MD, Department of Pediatrics, Children’s Hospital of Eastern Ontario, Ottawa, Ontario; 13K. Watanabe Duffy, MD, Department of Pediatrics, Children’s Hospital of Eastern Ontario, Ottawa, Ontario; 14A.M. Huber, MD, B. Lang, MD, S.E. Ramsey, MD, E. Stringer, MD, Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; 15J. Roth, MD, Department of Pediatrics, Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario; 16R. Schneider, MD, L. Spiegel, MD, S.M. Tse, MD, R.S. Yeung, MD, PhD, Department of Paediatrics, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada.

Funding Information:
The BBOP Study was supported by The Canadian Institutes of Health Research (FRN #82517); The Arthritis Society (Canada), Canadian Arthritis Network (SRI-IJD-01); University of Saskatchewan; The Clinical Research Centre of the Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; McGill University; Memorial University; Manitoba Institute of Child Health; Children's Health Research Trust Fund; Jim Pattison Children's Hospital Foundation of Saskatchewan; The Pediatric Rheumatic Disease Research and Innovation Laboratory, University of Saskatchewan; The Haslam Research Fund, University of Saskatchewan; and The Kleiman Fund, University of Saskatchewan.

Publisher Copyright:
© 2021 Journal of Rheumatology. All rights reserved.

ASJC Scopus Subject Areas

Immunology and Allergy
Rheumatology
Immunology

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

Acceder al documento

10.3899/jrheum.200391

Otros archivos y enlaces

Citar esto

@article{be52660b639b4c1086d004bc2e01874d,

title = "Soluble low-density lipoprotein receptor-related protein 1 in juvenile idiopathic arthritis",

abstract = "Objectives. This study aimed to expand knowledge about soluble low-density lipoprotein receptor-related protein 1 (sLRP1) in juvenile idiopathic arthritis ( JIA) by determining associations of sLRP1 levels in nonsystemic JIA patients with clinical and inflammatory biomarker indicators of disease activity. Methods. Plasma sLRP1 and 44 inflammation-related biomarkers were measured at enrollment and 6 months later in a cohort of 96 newly diagnosed Canadian patients with nonsystemic JIA. Relationships between sLRP1 levels and indicators of disease activity and biomarker levels were analyzed at both visits. Results. At enrollment, sLRP1 levels correlated negatively with age and active joint counts. Children showed significantly higher levels of sLRP1 than adolescents (mean ranks: 55.4 and 41.9, respectively; P = 0.02). Participants with 4 or fewer active joints, compared to those with 5 or more active joints, had significantly higher sLRP1 levels (mean ranks: 56.2 and 40.7, respectively; P = 0.006). At enrollment, considering the entire cohort, sLRP1 correlated negatively with the number of active joints (r = -0.235, P = 0.017). In the entire cohort, sLRP1 levels at enrollment and 6 months later correlated with 13 and 6 pro- and antiinflammatory biomarkers, respectively. In JIA categories, sLRP1 correlations with inflammatory markers were significant in rheumatoid factor-negative polyarticular JIA, oligoarticular JIA, enthesitis-related arthritis, and psoriatic arthritis at enrollment. Higher sLRP1 levels at enrollment increased the likelihood of absence of active joints 6 months later. Conclusion. Plasma sLRP1 levels correlate with clinical and biomarker indicators of short-term improvement in JIA disease activity, supporting sLRP1 as an upstream biomarker of potential utility for assessing JIA disease activity and outcome prediction.",

author = "{the BBOP Study Group} and Elham Rezaei and Newkirk, {Marianna M.} and Zhenhong Li and Gordon, {John R.} and Oen, {Kiem G.} and Benseler, {Susanne M.} and Gilles Boire and Cabral, {David A.} and Sarah Campillo and Ga{\"e}lle Ch{\'e}deville and Chetaille, {Anne Laure} and Paul Dancey and Ciaran Duffy and Duffy, {Karen Watanabe} and Kristin Houghton and Huber, {Adam M.} and Roman Jurencak and Bianca Lang and Morishita, {Kimberly A.} and Petty, {Ross E.} and Ramsey, {Suzanne E.} and Johannes Roth and Rayfel Schneider and Rosie Scuccimarri and Lynn Spiegel and Elizabeth Stringer and Tse, {Shirley M.L.} and Tucker, {Lori B.} and Turvey, {Stuart E.} and Yeung, {Rae S.M.} and Rosenberg, {Alan M.}",

note = "Funding Information: The BBOP Study was supported by The Canadian Institutes of Health Research (FRN #82517); The Arthritis Society (Canada), Canadian Arthritis Network (SRI-IJD-01); University of Saskatchewan; The Clinical Research Centre of the Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; McGill University; Memorial University; Manitoba Institute of Child Health; Children{\textquoteright}s Health Research Trust Fund; Jim Pattison Children{\textquoteright}s Hospital Foundation of Saskatchewan; The Pediatric Rheumatic Disease Research and Innovation Laboratory, University of Saskatchewan; The Haslam Research Fund, University of Saskatchewan; and The Kleiman Fund, University of Saskatchewan. 1E. Rezaei, MD, PhD, A.M. Rosenberg, MD, Departments of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan; 2M.M. Newkirk, PhD, Department of Medicine, McGill University Health Center, Montreal, Quebec; 3Z. Li, MSc, RC-CHUM, University of Montreal, Montreal, Quebec; 4J.R. Gordon, PhD, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan; 5K.G. Oen, MD, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba; 6S.M. Benseler, MD, PhD, Department of Pediatrics, Alberta Children{\textquoteright}s Hospital, University of Calgary, Calgary, Alberta; 7G. Boire, MD, D{\'e}partement de M{\'e}decine, Universit{\'e} de Sherbrooke, Sherbrooke, Quebec; 8D.A. Cabral, MD, K. Houghton, MD, K.A. Morishita, MD, R.E. Petty, MD, PhD, L.B. Tucker, MD, S.E. Turvey, MD, Department of Pediatrics, British Columbia Children{\textquoteright}s Hospital, Vancouver, British Columbia; 9S. Campillo, MD, G. Ch{\'e}deville, MD, R. Scuccimarri, MD, Department of Pediatrics, McGill University Health Center, Montreal, Quebec; 10A.L. Chetaille, MD, D{\'e}partement de M{\'e}decine le Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec; 11P. Dancey, MD, Department of Pediatrics, Janeway Children{\textquoteright}s Health and Rehabilitation Centre, St. John{\textquoteright}s, Newfoundland; 12C. Duffy, MD, R. Jurencak, MD, Department of Pediatrics, Children{\textquoteright}s Hospital of Eastern Ontario, Ottawa, Ontario; 13K. Watanabe Duffy, MD, Department of Pediatrics, Children{\textquoteright}s Hospital of Eastern Ontario, Ottawa, Ontario; 14A.M. Huber, MD, B. Lang, MD, S.E. Ramsey, MD, E. Stringer, MD, Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; 15J. Roth, MD, Department of Pediatrics, Children{\textquoteright}s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario; 16R. Schneider, MD, L. Spiegel, MD, S.M. Tse, MD, R.S. Yeung, MD, PhD, Department of Paediatrics, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada. Funding Information: The BBOP Study was supported by The Canadian Institutes of Health Research (FRN #82517); The Arthritis Society (Canada), Canadian Arthritis Network (SRI-IJD-01); University of Saskatchewan; The Clinical Research Centre of the Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; McGill University; Memorial University; Manitoba Institute of Child Health; Children's Health Research Trust Fund; Jim Pattison Children's Hospital Foundation of Saskatchewan; The Pediatric Rheumatic Disease Research and Innovation Laboratory, University of Saskatchewan; The Haslam Research Fund, University of Saskatchewan; and The Kleiman Fund, University of Saskatchewan. Publisher Copyright: {\textcopyright} 2021 Journal of Rheumatology. All rights reserved.",

year = "2021",

month = may,

day = "1",

doi = "10.3899/jrheum.200391",

language = "English",

volume = "48",

pages = "760--766",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "5",

}

TY - JOUR

T1 - Soluble low-density lipoprotein receptor-related protein 1 in juvenile idiopathic arthritis

AU - the BBOP Study Group

AU - Rezaei, Elham

AU - Newkirk, Marianna M.

AU - Li, Zhenhong

AU - Gordon, John R.

AU - Oen, Kiem G.

AU - Benseler, Susanne M.

AU - Boire, Gilles

AU - Cabral, David A.

AU - Campillo, Sarah

AU - Chédeville, Gaëlle

AU - Chetaille, Anne Laure

AU - Dancey, Paul

AU - Duffy, Ciaran

AU - Duffy, Karen Watanabe

AU - Houghton, Kristin

AU - Huber, Adam M.

AU - Jurencak, Roman

AU - Lang, Bianca

AU - Morishita, Kimberly A.

AU - Petty, Ross E.

AU - Ramsey, Suzanne E.

AU - Roth, Johannes

AU - Schneider, Rayfel

AU - Scuccimarri, Rosie

AU - Spiegel, Lynn

AU - Stringer, Elizabeth

AU - Tse, Shirley M.L.

AU - Tucker, Lori B.

AU - Turvey, Stuart E.

AU - Yeung, Rae S.M.

AU - Rosenberg, Alan M.

N1 - Funding Information: The BBOP Study was supported by The Canadian Institutes of Health Research (FRN #82517); The Arthritis Society (Canada), Canadian Arthritis Network (SRI-IJD-01); University of Saskatchewan; The Clinical Research Centre of the Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; McGill University; Memorial University; Manitoba Institute of Child Health; Children’s Health Research Trust Fund; Jim Pattison Children’s Hospital Foundation of Saskatchewan; The Pediatric Rheumatic Disease Research and Innovation Laboratory, University of Saskatchewan; The Haslam Research Fund, University of Saskatchewan; and The Kleiman Fund, University of Saskatchewan. 1E. Rezaei, MD, PhD, A.M. Rosenberg, MD, Departments of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan; 2M.M. Newkirk, PhD, Department of Medicine, McGill University Health Center, Montreal, Quebec; 3Z. Li, MSc, RC-CHUM, University of Montreal, Montreal, Quebec; 4J.R. Gordon, PhD, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan; 5K.G. Oen, MD, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba; 6S.M. Benseler, MD, PhD, Department of Pediatrics, Alberta Children’s Hospital, University of Calgary, Calgary, Alberta; 7G. Boire, MD, Département de Médecine, Université de Sherbrooke, Sherbrooke, Quebec; 8D.A. Cabral, MD, K. Houghton, MD, K.A. Morishita, MD, R.E. Petty, MD, PhD, L.B. Tucker, MD, S.E. Turvey, MD, Department of Pediatrics, British Columbia Children’s Hospital, Vancouver, British Columbia; 9S. Campillo, MD, G. Chédeville, MD, R. Scuccimarri, MD, Department of Pediatrics, McGill University Health Center, Montreal, Quebec; 10A.L. Chetaille, MD, Département de Médecine le Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec; 11P. Dancey, MD, Department of Pediatrics, Janeway Children’s Health and Rehabilitation Centre, St. John’s, Newfoundland; 12C. Duffy, MD, R. Jurencak, MD, Department of Pediatrics, Children’s Hospital of Eastern Ontario, Ottawa, Ontario; 13K. Watanabe Duffy, MD, Department of Pediatrics, Children’s Hospital of Eastern Ontario, Ottawa, Ontario; 14A.M. Huber, MD, B. Lang, MD, S.E. Ramsey, MD, E. Stringer, MD, Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; 15J. Roth, MD, Department of Pediatrics, Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario; 16R. Schneider, MD, L. Spiegel, MD, S.M. Tse, MD, R.S. Yeung, MD, PhD, Department of Paediatrics, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada. Funding Information: The BBOP Study was supported by The Canadian Institutes of Health Research (FRN #82517); The Arthritis Society (Canada), Canadian Arthritis Network (SRI-IJD-01); University of Saskatchewan; The Clinical Research Centre of the Centre Hospitalier Universitaire de Sherbrooke; University of British Columbia; McGill University; Memorial University; Manitoba Institute of Child Health; Children's Health Research Trust Fund; Jim Pattison Children's Hospital Foundation of Saskatchewan; The Pediatric Rheumatic Disease Research and Innovation Laboratory, University of Saskatchewan; The Haslam Research Fund, University of Saskatchewan; and The Kleiman Fund, University of Saskatchewan. Publisher Copyright: © 2021 Journal of Rheumatology. All rights reserved.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - Objectives. This study aimed to expand knowledge about soluble low-density lipoprotein receptor-related protein 1 (sLRP1) in juvenile idiopathic arthritis ( JIA) by determining associations of sLRP1 levels in nonsystemic JIA patients with clinical and inflammatory biomarker indicators of disease activity. Methods. Plasma sLRP1 and 44 inflammation-related biomarkers were measured at enrollment and 6 months later in a cohort of 96 newly diagnosed Canadian patients with nonsystemic JIA. Relationships between sLRP1 levels and indicators of disease activity and biomarker levels were analyzed at both visits. Results. At enrollment, sLRP1 levels correlated negatively with age and active joint counts. Children showed significantly higher levels of sLRP1 than adolescents (mean ranks: 55.4 and 41.9, respectively; P = 0.02). Participants with 4 or fewer active joints, compared to those with 5 or more active joints, had significantly higher sLRP1 levels (mean ranks: 56.2 and 40.7, respectively; P = 0.006). At enrollment, considering the entire cohort, sLRP1 correlated negatively with the number of active joints (r = -0.235, P = 0.017). In the entire cohort, sLRP1 levels at enrollment and 6 months later correlated with 13 and 6 pro- and antiinflammatory biomarkers, respectively. In JIA categories, sLRP1 correlations with inflammatory markers were significant in rheumatoid factor-negative polyarticular JIA, oligoarticular JIA, enthesitis-related arthritis, and psoriatic arthritis at enrollment. Higher sLRP1 levels at enrollment increased the likelihood of absence of active joints 6 months later. Conclusion. Plasma sLRP1 levels correlate with clinical and biomarker indicators of short-term improvement in JIA disease activity, supporting sLRP1 as an upstream biomarker of potential utility for assessing JIA disease activity and outcome prediction.

AB - Objectives. This study aimed to expand knowledge about soluble low-density lipoprotein receptor-related protein 1 (sLRP1) in juvenile idiopathic arthritis ( JIA) by determining associations of sLRP1 levels in nonsystemic JIA patients with clinical and inflammatory biomarker indicators of disease activity. Methods. Plasma sLRP1 and 44 inflammation-related biomarkers were measured at enrollment and 6 months later in a cohort of 96 newly diagnosed Canadian patients with nonsystemic JIA. Relationships between sLRP1 levels and indicators of disease activity and biomarker levels were analyzed at both visits. Results. At enrollment, sLRP1 levels correlated negatively with age and active joint counts. Children showed significantly higher levels of sLRP1 than adolescents (mean ranks: 55.4 and 41.9, respectively; P = 0.02). Participants with 4 or fewer active joints, compared to those with 5 or more active joints, had significantly higher sLRP1 levels (mean ranks: 56.2 and 40.7, respectively; P = 0.006). At enrollment, considering the entire cohort, sLRP1 correlated negatively with the number of active joints (r = -0.235, P = 0.017). In the entire cohort, sLRP1 levels at enrollment and 6 months later correlated with 13 and 6 pro- and antiinflammatory biomarkers, respectively. In JIA categories, sLRP1 correlations with inflammatory markers were significant in rheumatoid factor-negative polyarticular JIA, oligoarticular JIA, enthesitis-related arthritis, and psoriatic arthritis at enrollment. Higher sLRP1 levels at enrollment increased the likelihood of absence of active joints 6 months later. Conclusion. Plasma sLRP1 levels correlate with clinical and biomarker indicators of short-term improvement in JIA disease activity, supporting sLRP1 as an upstream biomarker of potential utility for assessing JIA disease activity and outcome prediction.

UR - http://www.scopus.com/inward/record.url?scp=85105642778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105642778&partnerID=8YFLogxK

U2 - 10.3899/jrheum.200391

DO - 10.3899/jrheum.200391

M3 - Article

C2 - 33060303

AN - SCOPUS:85105642778

SN - 0315-162X

VL - 48

SP - 760

EP - 766

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 5

ER -

Soluble low-density lipoprotein receptor-related protein 1 in juvenile idiopathic arthritis

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto